Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Average PT from Brokerages

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) have earned an average rating of “Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $37.17.

Several equities analysts have weighed in on KNSA shares. Citigroup started coverage on Kiniksa Pharmaceuticals in a report on Thursday. They issued a “buy” rating and a $40.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock opened at $22.61 on Thursday. The firm’s 50 day moving average price is $19.99 and its two-hundred day moving average price is $22.16. Kiniksa Pharmaceuticals has a 52-week low of $16.56 and a 52-week high of $28.15. The stock has a market cap of $1.64 billion, a PE ratio of -161.49 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The firm had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm’s quarterly revenue was up 46.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.35 EPS. As a group, sell-side analysts predict that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals

In other news, CAO Michael R. Megna sold 9,051 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the sale, the chief accounting officer now directly owns 26,528 shares in the company, valued at approximately $595,553.60. This trade represents a 25.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 36,372 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00. Following the completion of the sale, the chief financial officer now owns 22,958 shares in the company, valued at approximately $510,815.50. The trade was a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,423 shares of company stock valued at $1,541,812 over the last ninety days. 54.57% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of hedge funds have recently made changes to their positions in KNSA. Quarry LP bought a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth about $50,000. Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at about $61,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at about $189,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at about $158,000. Finally, Bellevue Group AG acquired a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at about $160,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.